Alpha MSH: The Endogenous Melanocortin Peptide and Its Receptor Family

Alpha MSH is an endogenous melanocortin peptide produced through processing of the proopiomelanocortin precursor, POMC. It acts as a ligand at members of the melanocortin receptor family. This makes the molecule a biological reference for laboratory work on receptor systems, but it does not make every related ligand or every reported finding equivalent.

The materials discussed are for laboratory research use only. They are not for human or veterinary use. This page separates molecular identity, receptor subtype, assay design and evidence type. Background pages cover what peptides are and broader peptide research basics.

What alpha MSH is as a molecule

Alpha MSH belongs to the melanocortin peptides generated from POMC processing. The alpha MSH hormone is therefore an endogenous peptide product rather than a name for the whole precursor or for the receptor family. The literature writes the same endogenous molecule as α-MSH and as alpha-melanocyte-stimulating hormone. Neither spelling identifies a synthetic derivative merely because that derivative was designed with the endogenous peptide as its reference.

That distinction sets the scope of an alpha MSH structure record. A defensible record identifies which molecular material was examined and whether it was endogenous alpha MSH, a related endogenous peptide or a deliberately modified analogue. The eight cited publications do not provide a common abstract-level specification for sequence, chain length, molecular mass or database identifiers. Those details are consequently not added here rather than filled from outside the bounded source set.

Alpha MSH function is best resolved experimentally into a receptor, model and measured endpoint. Dall’Olmo and colleagues review the molecular biology of alpha MSH with the emphasis on its tumour-related properties and on the alpha-MSH/MC1R axis, a role the review itself calls debated (review, PMID 37608347, DOI 10.1186/s12967-023-04405-y). Singh and Mukhopadhyay review reported antimicrobial and immunomodulatory observations for the endogenous peptide and, expressly, for its C-terminal fragments (review, PMID 25140322, DOI 10.1155/2014/874610). Both are secondary syntheses, not new experiments with one standardised material.

The melanocortin receptor family: MC1R to MC5R

The melanocortin system includes five receptor subtypes: MC1R, MC2R, MC3R, MC4R and MC5R. Gantz and Fong describe the system as POMC-derived peptides, five receptors, two endogenous antagonists and two ancillary proteins (review, PMID 12556347, DOI 10.1152/ajpendo.00434.2002). The numbering marks distinct subtypes, not stages on a scale. MC5R is not a higher degree of the property represented by MC1R.

Each melanocortin receptor is therefore an experimental target with its own identity. An observation at one subtype cannot be silently reassigned to another. Likewise, an alpha-MSH receptor result needs the subtype, expression system and readout attached to it. Family membership provides a map for organising experiments; it does not provide a single class-wide response.

This point also limits overreading of receptor language. A publication may discuss several receptors while reporting a particular experiment in only one receptor system. The publication-level topic locates the work; the experiment-level evidence determines which finding can be attributed to which model.

What receptor selectivity means in an assay

Receptor selectivity is a comparison made under defined conditions: its interpretation depends at minimum on cell line, receptor expression, ligand identity, incubation conditions and signalling endpoint. A receptor binding experiment and a receptor activation experiment answer different questions. A cAMP readout is one signalling endpoint, not a complete description of every molecular event.

Grieco and colleagues ran a D-amino acid scan of gamma-MSH — a POMC-derived peptide, not the reference substance of this page. Binding and intracellular cAMP accumulation were measured at human MC3R, MC4R and MC5R. Native gamma-MSH bound weakly at all three, with a selectivity of one to two orders of magnitude at the MC3R. Most single D-isomer replacements weakened binding; two analogues departed from that pattern: D-Trp8 reached an IC50 of 6 nM at the MC3R with a selectivity gain of two orders of magnitude, while D-Phe6 reached 8.8 nM without subtype selectivity. The series shows in measured data that binding strength and subtype selectivity are separable quantities: D-Trp8 raised both, while D-Phe6 raised affinity alone. One change of configuration can move the one without the other. The finding belongs to gamma-MSH and to that platform: it shows which details a selectivity result requires, not what alpha MSH does at a receptor (binding and cAMP measurements at human MC3R, MC4R and MC5R, PMID 11150170, DOI 10.1021/jm000211e).

Selectivity therefore should not be detached from the assay configuration. Where two publications differ in cell line, expression level, timing, controls or readout, a difference between their reported values may reflect method as well as ligand; direct comparison requires equivalent platforms and matched conditions. The guide to study model definitions provides the corresponding model vocabulary.

Melanogenesis and inflammatory markers can appear as named laboratory endpoints in cell-based assays or preclinical models. Such endpoints remain measurements in those stated systems and establish no general property of alpha MSH across receptor subtypes.

Endogenous peptide and synthetic analogues are not interchangeable

Synthetic analogues can be designed from an endogenous reference while differing from it in sequence or structural constraint. Hadley and Dorr name both design types in the class: melanotan I as a linear peptide, melanotan II as a cyclic truncated peptide (review and historical article, PMID 16412534, DOI 10.1016/j.peptides.2005.01.029). Here, linear and cyclic describe structural features only; neither description establishes an experimental ranking.

Hadley and colleagues name two synthetic analogues in a publication title (review, PMID 9760697, DOI 10.1007/0-306-47384-4_25). With no abstract at the index, the record is carried for bibliography only and supports no statement here. Their shared placement in one publication makes them neither one material nor endogenous alpha MSH. That class-level history, including its record that analogues of the class entered clinical testing, still requires molecule-level assignment before a finding is reused.

Dorr and colleagues examined melanotan-II as a cyclic test substance in a single-blind, placebo-controlled phase-I pilot study in three male volunteers (PMID 8637402, DOI 10.1016/0024-3205(96)00160-9). This finding belongs to that identified analogue and that study design, not to endogenous alpha MSH. The catalogue link to a synthetic analogue in the catalogue records class context only; class membership makes no statement about an individual material, a batch or an experimental result.

Brzoska and colleagues review alpha-MSH related peptides that act beyond the pharmacophore rather than peptides sharing it (review, PMID 21222263, DOI 10.1007/978-1-4419-6354-3_8). The case they report is the instructive one: KPV, the C-terminal tripeptide, lacks the entire sequence motif required for binding to any known melanocortin receptor, and the review nevertheless records anti-inflammatory activity for it. A fragment can therefore depart from the parent molecule’s receptor route altogether. Similarity can justify a research question; it cannot answer the identity question in advance.

What the cited evidence base actually is

This source set contains eight publications. Six are reviews and therefore secondary literature: Singh and Mukhopadhyay 2014; Dall’Olmo and colleagues 2023; Brzoska 2010; Gantz and Fong 2003; Hadley and colleagues 1998; and Hadley and colleagues 2006, which PubMed also classifies as a historical article. Hadley 1998 carries no abstract at the index and bears no statement here, so five contribute content. The remaining two report primary measurements: Grieco 2000 at receptor level, and Dorr 1996, the phase-I pilot in three male volunteers concerning a synthetic cyclic analogue.

There is no human intervention study of endogenous alpha MSH itself in the cited evidence base. The sole human study cannot fill that gap because its test substance was a different molecule. Counting six reviews as six additional experiments would misstate the composition of the evidence.

The reviews serve distinct purposes here. Gantz and Fong support the five-subtype receptor map. Dall’Olmo and colleagues and Singh and Mukhopadhyay support molecule-level orientation. Brzoska supports the separation of related peptides from the endogenous reference. Hadley 2006 places synthetic designs in class-level historical context. None of them replaces a primary assay record for a new experimental claim.

Why substance identity comes before any published finding

Interpretation begins with the material: establish whether the record concerns endogenous alpha MSH, another POMC-derived peptide or a synthetic analogue. Then identify receptor subtype, model, comparator, conditions and endpoint. Only after those fields match should a published observation be considered relevant to a planned assay.

Batch evidence is a separate layer. Literature identifies what authors reported about a stated substance in stated models; it establishes neither identity nor purity of supplied material. Purity is supported only batch by batch through the corresponding Certificate of Analysis. A family name, receptor profile and batch result should remain separate, traceable fields.

This ordering also makes discrepancies easier to trace: an apparent conflict may arise from different molecules, receptor subtypes or readouts rather than from opposing results. Recording identity before endpoint guards against that category error.

What does not follow from this evidence base

The cited reviews do not establish one universal receptor profile for every melanocortin-related molecule, and they do not make endogenous alpha MSH interchangeable with a linear or cyclic analogue. Shared ancestry, shared publication context or activity observed within one assay does not demonstrate molecular equality.

Cell-based assays and animal models do not establish findings in humans. The phase-I pilot in humans concerns its named synthetic test substance only and cannot be reassigned to the endogenous reference.

Finally, this source set does not document sequence, chain length, molecular mass, register identifiers or batch purity for alpha MSH at the required abstract level. Those fields remain absent rather than being inferred. The evidence supports a disciplined reference map: molecule first, receptor second, assay and model third, measured endpoint last.

Sources

1. Singh M, Mukhopadhyay K. “Alpha-melanocyte stimulating hormone: an emerging anti-inflammatory antimicrobial peptide.” BioMed Research International. 2014. Review. PMID 25140322. DOI: 10.1155/2014/874610.
2. Dall’Olmo L, et al. “Alpha-melanocyte stimulating hormone (α-MSH): biology, clinical relevance and implication in melanoma.” Journal of Translational Medicine. 2023. Review. PMID 37608347. DOI: 10.1186/s12967-023-04405-y.
3. Brzoska T, et al. “Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore.” Advances in Experimental Medicine and Biology. 2010. Review. PMID 21222263. DOI: 10.1007/978-1-4419-6354-3_8.
4. Gantz I, Fong TM. “The melanocortin system.” American Journal of Physiology-Endocrinology and Metabolism. 2003. Review. PMID 12556347. DOI: 10.1152/ajpendo.00434.2002.
5. Grieco P, et al. “D-Amino acid scan of gamma-melanocyte-stimulating hormone: importance of Trp(8) on human MC3 receptor selectivity.” Journal of Medicinal Chemistry. 2000. Binding and cAMP measurements, human MC3R/MC4R/MC5R. PMID 11150170. DOI: 10.1021/jm000211e.
6. Hadley ME, et al. “Discovery and development of novel melanogenic drugs. Melanotan-I and -II.” Pharmaceutical Biotechnology. 1998. Review. No abstract at the index; carried for bibliography only. PMID 9760697. DOI: 10.1007/0-306-47384-4_25.
7. Hadley ME, et al. “Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.” Peptides. 2006. Review and historical article. PMID 16412534. DOI: 10.1016/j.peptides.2005.01.029.
8. Dorr RT, et al. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sciences. 1996. Phase-I pilot study in humans. PMID 8637402. DOI: 10.1016/0024-3205(96)00160-9.